l General Information |
Product Name | Ticagrelor |
General description | Ticagrelor is a P2Y12 Platelet Inhibitor. |
Synonym | (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; AZD 6140 |
Purity | ≥98.0%(HPLC) | CAS Number | 274693-27-5 |
Formula | C23H28F2N6O4S | Molecular Weight | 522.57 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ≥50mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist with Ki of 2 nM. The mechanism of action of ticagrelor is as a Phenylalanine Hydroxylase Activator, and P2Y12 Receptor Antagonist, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 3A5 Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of ticagrelor is by means of Decreased Platelet Aggregation. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
